BETA · NSE
Beta Drugs Limited
₹2,055.2
-1.90% (-₹39.8)
Prev. close
₹2,095
Volume
14,462
Delivery %
55.5%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Beta Drugs Limited
Beta Drugs Limited develops, manufactures, and sells anti-cancer bulk drugs and finished dosages in India. The company offers cosmeceutical and oncology products. It also manufactures active pharmaceutical ingredients (API) and pharmaceutical formulation intermediates (PFI). The company exports its products. Beta Drugs Limited was founded in 1985 and is based in Panchkula, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Rahul Batra
Headquarters
Panchkula
Employees
455
Website
betadrugslimited.comExchange
View on NSE ↗Key stats
Market cap
₹2,074.63 Cr
P/E ratio (TTM)
46.5
EPS (TTM)
₹44.19
Beta (1Y · daily vs NIFTY 50)
0.98
Beta (5Y · monthly vs NIFTY 50)
0.71
Shares float
35.86 L
EPS · quarter ended Jun 2026
₹14.78
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide. Net income and EBITDA are omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹227.11 Cr | ₹295.71 Cr | ₹362.36 Cr | ₹384.83 Cr | |
| EBITDA | — | — | ₹53.75 Cr | ₹61.21 Cr | ₹76.47 Cr | ₹86.86 Cr |
| — | — | ₹30.72 Cr | ₹36.44 Cr | ₹42.42 Cr | ₹41.48 Cr | |
| Diluted EPS | — | — | ₹30.43 | ₹37.9 | ₹42.02 | ₹40.92 |
Revenue, Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Net income, Tax provision, Other income, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Net income for Mar 2026 could not be independently verified against the company's own annual report: this page shows ₹41.48 Cr while the annual report gives ₹14.33 Cr (65.4% apart).
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹118.00 Cr | ₹158.00 Cr | ₹198.00 Cr | ₹254.00 Cr | ₹436.00 Cr | ₹496.00 Cr | |
| — | — | ₹20.33 Cr | ₹14.71 Cr | ₹138.06 Cr | ₹147.81 Cr | |
| Stockholders' equity | ₹69.00 Cr | ₹93.00 Cr | ₹123.00 Cr | ₹158.00 Cr | ₹197.00 Cr | ₹245.00 Cr |
Current assets, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹19.00 Cr | ₹30.00 Cr | ₹23.00 Cr | ₹31.00 Cr | ₹36.00 Cr | ₹37.00 Cr | |
| Investing cash flow | — | — | ₹-19.07 Cr | ₹-13.97 Cr | ₹-35.72 Cr | ₹-51.39 Cr |
| ₹-8.00 Cr | ₹-1.00 Cr | ₹-2.00 Cr | ₹-7.00 Cr | ₹118.00 Cr | ₹-8.00 Cr | |
| Capital expenditure | ₹-6.00 Cr | ₹-19.00 Cr | ₹-18.00 Cr | ₹-12.00 Cr | ₹-37.00 Cr | ₹-53.00 Cr |
| End cash position | — | — | ₹19.16 Cr | ₹28.63 Cr | ₹147.02 Cr | ₹124.85 Cr |
Depreciation & amortization, Investing cash flow, Dividends paid, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21 | Mar 22–Dec 22(4Q) | Mar 23 | Jun 23 | Sep 23 | Dec 23 | Mar 24 | Jun 24–Sep 25(8Q) | Dec 25 | Mar 26 | May 26–Jun 26(2Q) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 66.68% | 66.71% | 66.71% | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 64.90% | 64.63% | 59.10% |
| Public | 33.31% | 33.30% | 33.29% | 33.27% | 33.26% | 33.27% | 33.26% | 33.25% | 33.27% | 35.10% | 35.37% | 40.90% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Beta Drugs Limited | ₹2,074.63 Cr | ₹2,055.2 | 46.5 | 8.48 | 16.9% | 0.60 | +6.2% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Beta Drugs Q2 FY27 Preview & Trends
Beta Drugs' Q2 FY27 results date is unconfirmed, with an outer deadline of November 14, 2026, for publication. The company's stock traded at Rs 2,075.80 on September 17, 2026, up 0.53%. Q1 FY27 net profit was Rs 16.00 crore, compared to a Q2 FY26 profit of Rs 12.00 crore.
Beta Drugs Shares Soar 17% After Q1 PAT Jumps 41% and Margin Expansion
Trade Brains · 2 months ago